Hemoglobin Electrophoresis

Your red blood cells carry a protein called hemoglobin, and it comes in several forms. Most adults make one dominant type, but millions of people worldwide carry inherited variants they may never know about. These variants can cause chronic anemia, painful episodes, organ damage, or nothing at all, depending on which ones you carry and in what combination. Hemoglobin electrophoresis separates and measures each type, giving you the full picture.

A standard complete blood count (CBC) can tell you that your red blood cells look small or that your hemoglobin is low. But it cannot tell you why. Is it iron deficiency? A thalassemia trait? A sickle cell variant? This panel answers that question by mapping the exact composition of hemoglobin in your blood, turning a vague finding into a specific diagnosis.

What This Panel Reveals

Normal adult hemoglobin is dominated by Hemoglobin A1, which should make up roughly 95% to 98% of the total. A smaller fraction, Hemoglobin A2, normally runs between 2.0% and 3.5%. Fetal hemoglobin (Hemoglobin F) is the oxygen carrier that kept you alive before birth; in adults, it typically drops below 2%. The remaining tests, Hemoglobin S, C, D, and E, should normally be absent. When any of these variants appear, or when the proportions shift, the panel reveals an inherited hemoglobin disorder.

These disorders fall into two broad categories. Structural variants are hemoglobin molecules built from an altered gene, such as Hemoglobin S (the sickle variant) or Hemoglobin C. Thalassemias are conditions where the body makes too little of a normal hemoglobin chain, shifting the proportions of A1, A2, and F without necessarily producing an abnormal variant. This panel catches both.

Why Carrier Status Matters

You inherit two copies of each hemoglobin gene, one from each parent. Carrying one altered copy (called a trait) usually causes no symptoms. Sickle cell trait, for example, affects roughly 1 in 13 African Americans, about 8% of that population. Most carriers live entirely normal lives. But if two carriers have a child together, that child has a 1 in 4 chance of inheriting both altered copies and developing full disease.

Sickle cell disease affects approximately 100,000 people in the United States and roughly 300,000 newborns worldwide each year. Hemoglobin C trait is carried by about 2% to 3% of African Americans. Hemoglobin E is the most common hemoglobin variant globally, with carrier rates reaching 30% or higher in parts of Thailand and Cambodia. Hemoglobin D is most prevalent in the Punjab region of India. Knowing your carrier status lets you make informed decisions about family planning and understand unexplained blood findings.

How to Read Your Results Together

The value of this panel is in the pattern, not any single number. A result showing Hemoglobin S at 35% to 45% with normal Hemoglobin A1 making up the rest indicates sickle cell trait, a carrier state that rarely causes problems. But Hemoglobin S above 80% with no Hemoglobin A1 present indicates sickle cell disease (HbSS), a serious condition requiring lifelong management.

Hemoglobin A2 is the quiet workhorse of this panel. When it rises above 3.5%, it is the single most reliable marker for beta thalassemia trait, even when the person feels perfectly fine and has only mildly small red blood cells. Without this measurement, beta thalassemia trait is frequently misdiagnosed as iron deficiency, leading to unnecessary iron supplementation.

Hemoglobin F tells a different story. In sickle cell disease, higher fetal hemoglobin levels are protective; they reduce the frequency of painful crises and organ damage. In adults without sickle cell disease, persistently elevated Hemoglobin F may indicate hereditary persistence of fetal hemoglobin (a benign condition) or certain bone marrow disorders that deserve investigation.

Compound Conditions the Panel Uncovers

Some of the most clinically significant findings occur when two different variants appear together. Hemoglobin SC disease (one copy of HbS plus one copy of HbC) causes a milder but still serious form of sickle cell disease, with particular risk of eye complications and bone damage. Hemoglobin S combined with beta thalassemia (S/beta-thal) produces another form of sickle cell disease whose severity depends on whether the thalassemia gene makes some normal hemoglobin or none at all.

Hemoglobin E combined with beta thalassemia (E/beta-thal) is one of the most common severe hemoglobin disorders in Southeast Asia, causing moderate to severe anemia that can require regular blood transfusions. None of these compound conditions can be identified by a CBC alone. Only the full electrophoresis pattern makes the diagnosis clear.

When Results Can Be Misleading

Iron deficiency can lower Hemoglobin A2 levels, masking beta thalassemia trait. If you are iron deficient and your Hemoglobin A2 comes back in the normal range, a repeat test after correcting the iron deficiency may reveal a previously hidden elevation. This is one of the most common diagnostic pitfalls with this panel.

Recent blood transfusions introduce donor hemoglobin into your bloodstream, which can distort every measurement on the panel. If you have received a transfusion in the past three months, your results may not reflect your own hemoglobin composition. Certain medications, including hydroxyurea (used to treat sickle cell disease), intentionally raise Hemoglobin F levels, which changes the expected pattern.

Tracking Over Time

For most people, hemoglobin electrophoresis results are stable across a lifetime because the underlying genetics do not change. A single test is usually definitive for carrier identification. However, serial testing becomes valuable in specific situations: monitoring Hemoglobin F levels in people with sickle cell disease on hydroxyurea therapy, tracking disease progression in thalassemia, or confirming results after correcting iron deficiency.

If you are managing sickle cell disease, your Hemoglobin F level is one of the most meaningful numbers to track. Studies of adults with sickle cell disease show that those with higher fetal hemoglobin levels experience fewer pain crises and have better long term outcomes. Your treatment team will use serial electrophoresis to gauge whether therapy is working.

What to Do with Your Results

If every variant comes back at zero and your Hemoglobin A1, A2, and F are within normal ranges, you do not carry a detectable hemoglobin disorder. No follow up is needed from this panel.

If you are found to carry a trait (one copy of any variant), the most important next step is ensuring your partner is tested before or during pregnancy planning. Two carriers of the same variant have a 25% chance of having a child with full disease. Genetic counseling can walk you through the specific risks for your combination.

If the panel reveals a pattern consistent with disease rather than trait, such as absent Hemoglobin A1 with high Hemoglobin S, you should see a hematologist. Sickle cell disease, thalassemia major, and compound inherited hemoglobin disorders all require specialized management. Early identification allows treatment to begin before organ damage accumulates.

If your Hemoglobin A2 is elevated and you have small red blood cells on your CBC, the combination strongly points to beta thalassemia trait. Adding an iron panel can help confirm that the small cells are not from iron deficiency, and genetic testing can provide definitive confirmation if needed.